Evaluation of the natural history of cancer of the cervix, implications for prevention. The Cancer Risk Management Model (CRMM) - Human papillomavirus and cervical components

Journal of Cancer Policy

Volumn 4, Issue , 2015, Pages 1-6

  Miller, Anthony B ^a   Gribble, Steve ^b   Nadeau, Claude ^c   Asakawa, Keiko ^c   Flanagan, William M ^c   Wolfson, Michael ^b   Coldman, Andrew ^d   Evans, William K ^e   Fitzgerald, Natalie ^f   Lockwood, Gina ^f   Popadiuk, Cathy ^g  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c STATISTICS CANADA   (Canada)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f Canadian Partnership Against Cancer   (Canada)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Cancer of the cervix; HPV infection; HPV vaccination; Microsimulation models

Indexed keywords

ARTICLE; CANCER RISK MANAGEMENT MODEL; COMPUTER MODEL; COMPUTER SIMULATION; DISEASE COURSE; DISEASE TRANSMISSION; HUMAN; IMMUNITY; INCIDENCE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; SCREENING; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 84949543379     PISSN: None     EISSN: 22135383     Source Type: Journal    
DOI: 10.1016/j.jcpo.2015.05.001     Document Type: Article

References (18)

1. Miller A.B. Conundrums in screening for cancer. Int J Cancer 2010, 126:1039-1046. Mini Review.
2. Dickinson J.A., Stankiewicz A., Popadiuk C., Pogany L., Onysko J., Miller A.B. Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Pub Health 2012, 12:992. 10.1186/1471-2458-12-992.
3. Popadiuk C., Stankiewicz A., Dickinson J., Pogany L., Miller A.B., Onysko J. Invasive cervical cancer incidence and mortality among Canadian women aged 15 to 29 and the impact of screening. J Obstet Gynaecol Can 2012, 34(12):1167-1176.
4. IARC handbooks on cancer prevention. Vol. 10: Cervix cancer screening 2005, IARC Press, Lyon.
5. Boyes D.A., Morrison B., Knox E.G., Draper G., Miller A.B. A cohort study of cervical cancer screening in British Columbia. Clin Invest Med 1982, 5:1-29.
6. Miller A.B., Lindsay J., Hill G.B. Mortality from cancer of the uterus in Canada and its relationship to screening for cancer of the cervix. Int J Cancer 1976, 17:602-612.
7. Task force appointed by the Conference of Deputy Ministers of Health, Cervical cancer screening programmes. Can Med Assoc J 1976, 114:1003-1033.
8. Walton R.J., Allen H.H., Anderson G.H., Boyes D.A., Blanchet M., Carmichael J., et al. Cervical cancer screening programmes: summary of the 1982 Canadian task force report. Can Med Assoc J 1982, 127:581-589.
9. Miller A.B., Anderson G., Brisson J., Laidlaw J., le Pitre N., Malcolmson P., et al. Report of a national workshop on screening for cancer of the cervix. Can Med Assoc J 1991, 145:1301-1325.
10. Evans W.K., Wolfson M.C., Flanagan W.M., Shin J., Goffin J., Miller A.B., et al. Canadian cancer risk management model: evaluation of cancer control. Int J Technol Assess Health Care 2013, 29:2. 10.1017/S0266462313000044.
11. Evans W.K., Wolfson M., Flanagan W.M., Shin J., Goffin J.R., Asakawa K., et al. The evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model. Long Cancer Manag 2012, 1:25-33.
12. Coldman A.J., Phillips N., Brisson N., Flanagan J., Wolfson W., Nadeau M.C. Evaluating colorectal cancer screening colorectal cancer screening options for Canada using the Cancer Risk Management Model. Curr Oncol 2015, 22(April (2)):e41-e50. 10.3747/co.22.2013.
13. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 64: Human papillomaviruses 1995, International Agency for Research on Cancer, Lyon.
14. Moore R.A., Ogilvie G., Fornika D., Moravan V., Brisson M., Amirabbasi-Beik M., et al. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women - implications for vaccination. Cancer Causes Control 2009, 20:1387-1396.
15. Ogilvie G.S., van Niekerk D.J., Krajden M., Martin R.E., Ehlen T.G., Ceballos K., et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL trial). BMC Cancer 2010, 10:111. 10.1186/1471-2407-10-111.
16. Van de Velde N., Brisson M., Boilya M.-C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28:7473-7484.
17. Statistics Canada Canadian Community Health Survey (CCHS), Cycle 3.1, Master data (12-months) 2013, Statistics Canada.
18. Canadian Partnership Against Cancer. The 2014 Cancer System. Performance report 2014, Canadian Partnership Against Cancer, Toronto.